Juno Therapeutics, Inc. (JUNO) Short Interest Update
Juno Therapeutics, Inc. (NASDAQ:JUNO) was the recipient of a large decrease in short interest during the month of September. As of September 29th, there was short interest totalling 9,481,474 shares, a decrease of 29.9% from the September 15th total of 13,519,026 shares. Based on an average daily trading volume, of 2,962,349 shares, the short-interest ratio is presently 3.2 days. Approximately 11.2% of the shares of the company are short sold.
Shares of Juno Therapeutics (JUNO) opened at 43.08 on Friday. The stock’s market cap is $4.52 billion. Juno Therapeutics has a 12-month low of $17.52 and a 12-month high of $47.03. The firm has a 50 day moving average price of $42.44 and a 200 day moving average price of $30.05.
Juno Therapeutics (NASDAQ:JUNO) last announced its quarterly earnings data on Thursday, August 3rd. The biopharmaceutical company reported ($0.96) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.72) by ($0.24). Juno Therapeutics had a negative net margin of 354.36% and a negative return on equity of 27.10%. The business had revenue of $21.30 million during the quarter, compared to analysts’ expectations of $15.59 million. During the same quarter in the previous year, the firm earned ($0.64) earnings per share. Juno Therapeutics’s revenue was down 22.8% on a year-over-year basis. On average, equities analysts expect that Juno Therapeutics will post ($3.08) EPS for the current year.
In other news, insider Sunil Agarwal sold 7,285 shares of the company’s stock in a transaction on Monday, October 2nd. The stock was sold at an average price of $44.76, for a total transaction of $326,076.60. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Richard Klausner sold 12,000 shares of the company’s stock in a transaction on Monday, August 7th. The shares were sold at an average price of $30.34, for a total value of $364,080.00. Following the transaction, the director now directly owns 788,985 shares in the company, valued at approximately $23,937,804.90. The disclosure for this sale can be found here. Insiders have sold a total of 85,004 shares of company stock worth $3,551,561 in the last ninety days. Insiders own 15.26% of the company’s stock.
Several institutional investors have recently made changes to their positions in JUNO. The Manufacturers Life Insurance Company lifted its position in shares of Juno Therapeutics by 7.2% in the second quarter. The Manufacturers Life Insurance Company now owns 3,405 shares of the biopharmaceutical company’s stock valued at $102,000 after acquiring an additional 228 shares in the last quarter. Pacad Investment Ltd. purchased a new stake in shares of Juno Therapeutics in the second quarter worth about $105,000. QS Investors LLC purchased a new stake in shares of Juno Therapeutics in the second quarter worth about $135,000. Great West Life Assurance Co. Can lifted its position in shares of Juno Therapeutics by 80.5% in the first quarter. Great West Life Assurance Co. Can now owns 8,518 shares of the biopharmaceutical company’s stock worth $189,000 after buying an additional 3,800 shares in the last quarter. Finally, Macquarie Group Ltd. purchased a new stake in shares of Juno Therapeutics in the second quarter worth about $248,000. Institutional investors and hedge funds own 67.38% of the company’s stock.
A number of brokerages recently issued reports on JUNO. Maxim Group reissued a “buy” rating and set a $56.00 price objective (up previously from $34.00) on shares of Juno Therapeutics in a report on Monday. Goldman Sachs Group, Inc. (The) reissued a “neutral” rating and set a $44.00 price objective on shares of Juno Therapeutics in a report on Friday, October 6th. Morgan Stanley reissued an “equal weight” rating and set a $43.00 price objective (up previously from $27.00) on shares of Juno Therapeutics in a report on Friday, October 6th. Barclays PLC began coverage on Juno Therapeutics in a report on Wednesday, September 6th. They set an “overweight” rating and a $55.00 price objective on the stock. Finally, Wells Fargo & Company reissued an “outperform” rating and set a $54.00 price objective (up previously from $35.00) on shares of Juno Therapeutics in a report on Tuesday, September 5th. Three research analysts have rated the stock with a sell rating, seven have given a hold rating and nine have given a buy rating to the company. The stock has an average rating of “Hold” and an average target price of $37.83.
About Juno Therapeutics
Juno Therapeutics, Inc (Juno) is a biopharmaceutical company, which is focused on developing cellular immunotherapies for the treatment of cancer. The Company is developing cell-based cancer immunotherapies based on its chimeric antigen receptor (CAR) and T cell receptor (TCR) technologies to genetically engineer T cells to recognize and kill cancer cells.
Receive News & Ratings for Juno Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Juno Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.